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Abstract
Background: Despite the availability of evidence-based guidelines for managing allergic rhinitis in primary care,
management of the condition in the United Kingdom (UK) remains sub-optimal. Its high prevalence and negative
effects on quality of life, school performance, productivity and co-morbid respiratory conditions (in particular,
asthma), and high health and societal costs, make this a priority for developing novel models of care. Recent
Australian research demonstrated the potential of a community pharmacy-based ‘goal-focused’ intervention to help
people with intermittent allergic rhinitis to self-manage their condition better, reduce symptom severity and
improve quality of life. In this pilot study we will assess the transferability of the goal-focused intervention to a UK
context, the suitability of the intervention materials, procedures and outcome measures and collect data to inform
a future definitive UK randomized controlled trial (RCT).
Methods/Design: A pilot cluster RCT with associated preliminary economic analysis and embedded qualitative
evaluation. The pilot trial will take place in two Scottish Health Board areas: Grampian and Greater Glasgow & Clyde.
Twelve community pharmacies will be randomly assigned to intervention or usual care group. Each will recruit 12
customers seeking advice or treatment for intermittent allergic rhinitis. Pharmacy staff in intervention pharmacies will
support recruited customers in developing strategies for setting and achieving goals that aim to avoid/minimize
triggers for, and eliminate/minimize symptoms of allergic rhinitis. Customers recruited in non-intervention pharmacies
will receive usual care. The co-primary outcome measures, selected to inform a sample size calculation for a future RCT,
are: community pharmacy and customer recruitment and completion rates; and effect size of change in the validated
mini-Rhinoconjunctivitis Quality of Life Questionnaire between baseline, one-week and six-weeks post-intervention.
Secondary outcome measures relate to changes in symptom severity, productivity, medication adherence and
self-efficacy. Quantitative data about accrual, retention and economic measures, and qualitative data about participants’
experiences during the trial will be collected to inform the future RCT.
Discussion: This work will lay the foundations for a definitive RCT of a community pharmacy-based ‘goal-focused’
self-management intervention for people with intermittent allergic rhinitis. Results of the pilot trial are expected to be
available in April 2013.
Trial registration: Current Controlled Trials ISRCTN43606442
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Background
Allergic rhinitis is a long-term condition with a high
prevalence (estimated at 26% in the UK [1]) that has
increased substantially in recent years [2]. Allergic rhinitis
has a significant negative impact on quality of life (QOL)
[3], productivity [4], school performance [5] and health
care costs [6,7]. Co-morbidity of allergic rhinitis with
asthma is common and is associated with poor asthma
outcomes [8-10]. Allergic rhinitis is a common presenting
condition in community-based health care, with commu-
nity pharmacies often representing the first point-of-contact
with health services [11].
Evidence-based guidelines for medical practitioners and
pharmacists have been introduced [12-14]. Two RCTs of
general practitioner (GP) guidelines for allergic rhinitis have
demonstrated improvements in patients’ allergic rhinitis-
related outcomes when guidelines are implemented, either
with [15] or without [16] specific training for primary care
staff. Nevertheless, primary care management of allergic
rhinitis is still sub-optimal in the UK [11,17,18] suggesting
that significant avoidable morbidity still exists. Care of
long-term conditions is increasingly shifting to the
community, opening up new opportunities for pharmacists
to effect sustainable changes in care delivery. Community
pharmacists are well placed to recognize and recommend
treatment for allergic rhinitis, particularly for intermittent
(seasonal) and mild cases [13], however, our searches
of the literature failed to identify any pharmacy-based
interventions for allergic rhinitis in the UK.
Two previous Australian studies suggested that a
community pharmacy-delivered goal-focused approach
has the potential to improve outcomes for patients with
allergic rhinitis [19-21]. Interpretation of the Australian
research was complicated by the lack of true comparison
populations, but despite this, the findings suggest that the
intervention could potentially improve allergic rhinitis
management. We propose undertaking a definitive RCT
in the UK, but prior to this, in accordance with Medical
Research Council guidance on the development of complex
interventions [22], the intervention must be piloted to
test transferability of the methods and measures used in
Australia, and derive estimates of effect sizes, participation
rates and completion rates that would be needed to fully
evaluate a similar intervention in the UK. Additionally,
our pilot trial will address limitations of the Australian
research [19-21] including lack of a true comparison
and collection of data for a comprehensive economic
evaluation.
Study design
The ‘Help for Hay Fever’ study is a pilot cluster RCT
with associated preliminary economic analysis and an
embedded qualitative study involving semi-structured
follow-up interviews with a sub-sample of participants
(community pharmacy staff and customers). Trained staff
(pharmacists and/or pharmacy assistants) will recruit
eligible customers with intermittent allergic rhinitis;
the intervention will be delivered immediately after
recruitment. Patient-reported outcomes will be measured
at baseline and again at one week and six weeks after
recruitment using a validated, disease-specific instrument
[23]. The trial will compare outcomes in people who
receive the intervention (intervention group) with those
receiving usual care. In addition, we will collect quantitative
data about accrual, retention and economic measures,
and qualitative data about participants’ experiences during
the trial, to inform a future full scale trial. Study materials
for this pilot trial will be based on those used in the
Australian studies [19-21].
Ethical considerations
This pilot trial will be conducted in accordance with NHS
research governance requirements and Good Clinical Prac-
tice Guidelines [24]. All necessary research ethics and NHS
Research and Development approvals have been obtained
from the North of Scotland Research Ethics Service and
from NHS Research Scotland Permissions Coordinating
Center respectively, prior to starting recruitment.
Aims and research questions
The aims are to adapt and pilot a community pharmacy-
delivered, goal-focused intervention for the self-manage-
ment of intermittent allergic rhinitis in Scotland, based
on previous research in Australia, and to collect data to
inform a future definitive Scottish RCT.
The research questions below will be addressed by two
parallel work streams (A and B) which will run simultan-
eously. The relationships between the timetabled activities
and the research questions are illustrated in Figure 1.
A. Questions about transferability of methods and
measures used previously in the Australian studies:
RQ:A1. Is the pharmacy staff training program suitable
for use in a Scottish setting?
RQ:A2. Is the allergic rhinitis intervention acceptable
and satisfactory to pharmacy staff delivering and
customers receiving the service in Scottish
pharmacies?
RQ:A3. Are the study materials and procedures
suitable for use in a Scottish setting?
RQ:A4. Are the outcome measures appropriate for use
in a Scottish setting?
B. Questions to inform a future definitive evaluation
by RCT:
RQ:B1. What are the likely pharmacy recruitment
rates and completion rates?
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RQ:B2. What are the likely customer recruitment rates
and completion rates?
RQ:B3. What effect sizes and variability can we expect?
RQ:B4. What sample size would be needed for the
definitive trial?
RQ:B5. What are the most appropriate health
economic outcome measures?
Participants and setting
Eligibility of community pharmacies entering the trial
All community pharmacies in NHS Grampian and NHS
Greater Glasgow & Clyde will be eligible to participate.
The only condition of inclusion will be that pharmacy staff
(at least one pharmacist and one pharmacy assistant)
are available to attend training if randomized to the
intervention group.
Eligibility of pharmacy customers entering the trial
Customers presenting with active symptoms of intermittent
allergic rhinitis at participating community pharmacies
will be eligible to take part. Each community pharmacy
will recruit 12 participants from customers attending the
pharmacy, aged ≥ 18 years and able to communicate in
English. Customers eligible for inclusion will be those with
active symptoms of allergic rhinitis, that is, respiratory/
ocular symptoms consistent with intermittent allergic
rhinitis as defined by ARIA (Allergic Rhinitis and its
Impact on Asthma) guidelines [12]. They will have had
two or more relevant symptoms for at least an hour on
fewer than four days per week, or for fewer than four
consecutive weeks. Those symptoms will include: runny
or blocked nose (both sides); itching nose and/or throat;
itching, sore and/or red eyes; and sudden bouts of sneezing.
Exclusion criteria are: pregnancy, terminal illness, and
current or recent involvement (within the past two years)
in an allergic rhinitis study.
Sampling and recruitment
Figure 2 shows a flowchart of the recruitment process.
Figure 1 Relationships between the timetabled activities and the research questions (RQ).
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Community pharmacies
An Email advertising the study, followed by a mailed
invitation to participate, will be sent to all community
pharmacies in the Grampian and Greater Glasgow &
Clyde Health Board areas (n = 130 and 314 respectively). A
stratified random sample of participants will be selected
from a list of all eligible community pharmacies responding
positively. Participating community pharmacies will receive
an honorarium of £10/ patient recruited at the end of the
recruitment period.
Pharmacy customers
Potential participants will be identified when they ask for
advice about symptoms, or request a named treatment,
or present a prescription for treatment of intermittent
allergic rhinitis. Eligible customers will be provided with
Figure 2 Flowchart of recruitment.
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a Participant Information Sheet explaining what the
study involves, advised that they may withdraw at any
time without prejudice to the quality of care they will
receive in the community pharmacy, and given the
opportunity to ask questions about the study. Those
agreeing to participate will be asked to give written
consent. To enhance follow-up rates, as recommended
in a recent Cochrane review [25], participants will
receive a gift voucher to the value of £10 as a thank you
for taking part.
Randomization
The unit of randomization will be the community phar-
macy. Using block randomization with a block size of
six, an independent statistician from the Medical Statistics
Team, Division of Applied Health Sciences, University of
Aberdeen, will select a random sample of 12 community
pharmacies, stratified by location (Grampian or Greater
Glasgow & Clyde) and by pharmacy status (independent/
small multiple/national multiple) from those responding
positively to the mailed invitation. Stratification by these
variables aims to account for any potential variation
resulting from urban/rural characteristics, pharmacy staff
and typical customers of included community pharmacies.
Six pharmacies will be allocated to each of the intervention
and usual care groups.
Intervention
Intervention group
With the aim of enhancing replicability of the intervention
for a future RCT, we have applied a reliable and valid
taxonomy of behavior change techniques (BCTs) from
recent UK-based research [26,27] to produce a clearer
specification of its components. Two authors (JF and LS)
independently specified each element of the intervention
and defined them using this taxonomy. The BCTs identi-
fied by each author were compared and any discrepancies
discussed until consensus was reached. The core BCTs
identified in the intervention are captured by four of the
taxonomy’s 16 clusters: Goals and planning (specific BCTs:
goal-setting (outcome); goal-setting (behavior); problem
solving; action planning), Natural consequences (specific
BCT: information about health consequences), Regulation
(specific BCT: pharmacological support), and Feedback
and Monitoring (specific BCTs: self-monitoring of behavior;
self-monitoring of outcome(s) of behavior). Additional
BCTs that may or may not be used, depending on the
personalized elements of the intervention, are part of the
clusters of: Regulation (BCT: social support), Antecedents
(BCTs: restructuring the physical environment; restructuring
the social environment) and Associations (BCT: prompts/
cues). Table 1 shows the output from this exercise and
how the BCTs are operationalized in the ‘Help for Hay
Fever’ intervention.
Community pharmacy staff
Recruitment and training of pharmacy staff will take
place over a period of three months. One pharmacist
and at least one pharmacy assistant from each of the six
intervention pharmacies will attend a three hour training
workshop; one workshop will be held in each of the
Grampian and Greater Glasgow & Clyde Health Board
areas. The training program will be a ‘refresher’ about
current best practice in allergic rhinitis and the ARIA
guidelines for pharmacy management of allergic rhinitis
[13]. The workshop will include training in self-
management theory, the use of goal-setting as a behavior
change technique and participant recruitment (including
taking consent). At the end of the workshop, partici-
pants will take part in a role play scenario, allowing
them the opportunity to experience the process of deliv-
ering the intervention. The training aims to motivate
pharmacy staff, for example, by giving them the confi-
dence to deliver the intervention and emphasizing how
the intervention could improve patients’ allergic rhinitis-
related QOL. As soon as possible after training, a re-
searcher will visit each intervention community pharmacy
to deliver the necessary study materials. During this visit,
the researcher will go through the training materials once
more with at least one staff member who had attended the
training evening. Pharmacy staff will then be given the op-
portunity to ask any remaining questions about the study
before commencing recruitment.
Community pharmacy customers
Recruitment of pharmacy customers will take place over
a period of four months. Pharmacy customers who are
eligible and willing will receive the one-off intervention
that was developed in Australia. In addition to advising
customers about treatment and management of allergic
rhinitis, pharmacy staff will provide them with a card
containing two pre-determined goals (‘Avoid/minimize
hay fever triggers’ and ‘Eliminate/minimize hay fever
symptoms’). This card provides space for participants to
record (in writing) their personal allergic rhinitis triggers
and symptoms; pharmacy staff will support them in for-
mulating action plans for achieving these two goals. Par-
ticipants will also receive printed information to take
home about allergic rhinitis symptoms, triggers and gen-
eral information.
Usual care group
Pharmacy staff randomized to the usual care arm will re-
ceive no training in allergic rhinitis. A researcher will
visit each of the six usual care community pharmacies to
deliver the study materials, and to train staff in recruit-
ment, consent taking and use of the data collection ma-
terials. Customer recruitment will begin immediately
after this visit. Recruitment of pharmacy staff and
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Table 1 Specifying the intervention using a taxonomy of behavior change techniques (BCTs) [22,23]
Core elements of the intervention
Label Definition How is it operationalized in the ‘Help for Hay Fever’ study?
Goals and planning
Goal-setting outcome Set or agree a goal defined in terms of a
positive outcome of wanted behavior.
Set a pre-determined outcome goal: ‘eliminate/minimize
symptoms.’
Goal-setting behavior Set or agree a goal defined in terms of
the behavior to be achieved.
Set a pre-determined behavior goal: ‘avoid/minimize triggers’.
Problem solving Analyze factors influencing the behavior
and generate or select strategies that
include overcoming barriers and/or
increasing facilitators.
Identify specific barriers to achieving optimum management of
hay fever, for example, not taking medication regularly, and
suggest personalized strategies to overcome this, for example,
provide prompts/cues for medication adherence.
Action planning Prompt detailed planning of performance
of the behavior.
Plan personalized strategies to achieve the two specified goals
(avoid/minimize triggers and eliminate/minimize symptoms)
and complete a personalized goals card:
a) Focus on personal symptoms and symptom triggers and
help the person to develop specific behavioral strategies to
achieve the goals.
b) Negotiate the strategies the person would like to use to
control the symptoms/triggers and ask them to write these on
the goals card.
Natural consequences
Information about health
consequences
Provide information about health consequences
of performing the behavior.
Present the likelihood of an improved quality of life, reduced
symptom severity, better productivity.
Regulation
Pharmacological support Provide, or encourage the use of or adherence
to, drugs to facilitate behavior change.
Advise on hay fever medications and encourage medication
adherence.
Feedback and monitoring
Self-monitoring of behavior Establish a method for the person to monitor
and record their behavior(s) as part of a
behavior change strategy.
Ask the person to record daily whether or not they have taken
their hay fever medication, using a diary booklet provided.
Self-monitoring of outcome(s)
of behavior
Establish a method for the person to monitor
and record the outcome(s) of their behavior
as part of a behavior change strategy.
Ask the person to record daily their symptom severity score
using a diary booklet provided.
Personalized elements of the intervention
Regulation
Social support (practical) Advise on, arrange, or provide practical help
(for example, from friends, relatives, colleagues,
‘buddies’ or staff) for performance of the behavior.
Provide if appropriate, based on discussion with customer about
how social contacts might facilitate trigger avoidance for example,
ask a friend, relative or neighbor to cut the grass for them.
Antecedents
Restructuring the physical
environment
Change, or advise to change the environment in
order to facilitate performance of the wanted
behavior or create barriers to the unwanted
behavior (other than prompts/cues, rewards
and punishments).
Provide if appropriate, based on discussion with customer about
any specific hay fever triggers.
a) Changes to physical environment might include moving indoor
pot plants; removing visible mould with bleach/ anti-mould
cleaner; closing windows.
Restructuring the social
environment
Change, or advise to change the social environment
in order to facilitate performance of the wanted
behavior or create barriers to the unwanted behavior
(other than prompts/cues, rewards and punishments).
b) Changes to social environment might include avoiding social
occasions that trigger symptoms, for example, outdoor picnics.
Associations
Prompts/cues Introduce or define environmental or social
stimulus with the purpose of prompting or
cueing the behavior.
Provide if appropriate, based on discussion with customer about
any barriers to the target behavior, for example, leaving hay fever
medication in an obvious place to remind people to take it in
the morning (beside car keys, next to toothbrush, and so on).
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customers in the usual care group will take place con-
temporaneously with the intervention group.
Outcome measures and instruments
Quantitative outcomes
The co-primary outcomes are:
 community pharmacy and pharmacy customer
recruitment and completion rates;
 effect size and variability of change in allergic
rhinitis-related QOL.
The decision about whether or not to undertake a
RCT will be informed by pharmacy and customer re-
cruitment and completion rates, and the sample size cal-
culation informed by the estimated effect size of the
mini-Rhinoconjunctivitis Quality of Life Questionnaire
(mini-RQLQ). This is a validated and widely used
disease-specific health status instrument, the psychomet-
ric properties and ‘minimally clinically important differ-
ences’ of which are well described [23]. The domains
covered by the mini-RQLQ are: activities; practical prob-
lems; nose symptoms; eye symptoms; and other symp-
toms. Although this pilot study is not powered to detect
any statistically significant between-group changes in
mini-RQLQ scores, the decision to proceed to full trial
will be informed by any trend in customer benefit of the
intervention; it is unlikely that a RCT will be undertaken
if no improvement or a deterioration in mini-RQLQ
score between groups is observed.
Our selected secondary outcome measures represent a
range of clinical indicators, social functioning and eco-
nomic outcomes that are relevant to allergic rhinitis
[23,28]:
 symptom severity using a 12-item scale from
Spector 2003 [29] adapted for use in the Australian
studies.
 productivity using the six-item Work Productivity
and Activity Impairment Questionnaire: Allergy
Specific [30,31] .
 medication adherence using the five-item
Medication Adherence Reporting Scale [32].
 self-efficacy using the Lorig six-item generic
instrument [33] adapted for use in the Australian
studies.
 health state utilities and quality adjusted life years
based on responses to the EQ-5D [34].
 pharmacy and health service costs.
 costs to patients and production effects.
A costing exercise will be undertaken to estimate the
direct costs of the intervention to pharmacy staff and
customers, including resources used in training, as well
as indirect production effects. Data will also be collected
about customers’ allergic rhinitis-related contacts with
health services and medication use during the six-week
follow-up period, both measured by patient self-report.
Data will be collected from both intervention and
usual care customers as described above. We recognize
that, as is the case in any trial collecting self-report data,
the action of completing the data collection instruments
may in itself contribute to changes in allergic rhinitis
management. However, we anticipate that any such ef-
fect is likely to be similar in both intervention and usual
care groups. Any between group differences are there-
fore unlikely to be attributable to any ‘Hawthorne effect’.
In addition to the above, data concerning the training
workshops will be collected from participating commu-
nity pharmacy staff in the intervention group. This data
will inform the training for a future RCT:
 training workshops will be evaluated using a
questionnaire based on the one used previously in
Australia [35]. It will cover satisfaction with and
acceptability of the training content, and the way in
which it is delivered.
 a multiple choice questionnaire, developed for this
study, will measure knowledge of allergic rhinitis
management and treatment, before and after the
training workshop.
Embedded qualitative study
Six weeks after recruitment, semi-structured telephone
exit interviews will be undertaken with a purposively se-
lected sub-sample of intervention customers (three from
each pharmacy, n = 18) representing a range of age, gen-
der and self-reported symptom severity scores. The
interview will elicit views on: acceptability, experiences
of, and satisfaction with the intervention; what worked
best for them; and acceptability of the measures used. A
quantitative question will be also be included to deter-
mine the maximum amount of money that clients in the
intervention group would have been willing to pay for
the service they received. The interview schedule will be
informed by the findings of the previous Australian
research.
Following completion of customer recruitment in
community pharmacies, semi-structured interviews with
at least one participating member of staff from each
intervention pharmacy will collect qualitative data about:
their experiences of implementing the intervention; per-
ceived benefits of and barriers to introducing it into
usual practice; and general issues around acceptability
of, and satisfaction with, the intervention. For the eco-
nomic analysis, we will assess the potential willingness
of intervention pharmacy staff to provide the interven-
tion under existing contract arrangements or through
Porteous et al. Trials 2013, 14:217 Page 7 of 10
http://www.trialsjournal.com/content/14/1/217
separate funding streams. A question will be also be
included to determine any additional fees that pharma-
cies would demand in order to provide the service to
the NHS or private paying clients. The interview sched-
ule will be informed by the findings of the previous
Australian research.
Data collection
Copies of our data collection instruments can be
obtained on application to the authors.
Using a ‘recruitment log’, staff in participating pharma-
cies who are responsible for recruitment will keep a tally
of the number of customers approached and record the
number accepting, the number declining, and the num-
ber excluded because they did not meet the inclusion
criteria. Data from the recruitment log will provide de-
nominators for calculating recruitment and completion
rates at the end of the study period, and allow realistic
estimation of the period required for recruitment.
All eligible customers in both intervention and usual
care groups who agree to participate will complete a
baseline questionnaire in the pharmacy, collecting data
about demographic characteristics and allergic rhinitis-
related outcome data including: QOL, symptom severity,
productivity, medication adherence and self-efficacy.
Additional data about participants’ allergic rhinitis his-
tory and their contact details will be collected by phar-
macy staff using forms provided for that purpose. To
inform the economic analysis, the staff member respon-
sible for recruiting individual customers will record the
time taken per customer, to advise about allergic rhinitis
management and (where appropriate) deliver the inter-
vention. All data collected in the community pharmacy
will be returned to the research team on the day of re-
cruitment to allow researchers to follow up recruited
customers in a timely fashion.
Each day in the week following recruitment, using a
diary booklet provided for the purpose, participants will
record an allergic rhinitis severity score (‘On a scale of 1
to 10, I think my symptoms have been…’) and their ad-
herence to allergic rhinitis medication (‘I have taken my
hay fever medication’; YES/NO). During that first week,
a copy of the same questionnaire used at baseline will be
mailed to all participants. This will be completed one
week after recruitment and returned, together with their
completed diary booklet (symptom severity and medica-
tion adherence) in a reply-paid envelope provided. Six
weeks after recruitment, all participants will receive an-
other postal questionnaire to collect a sub-set of the out-
come data (QOL and symptom severity), and additional
data to inform a future economic evaluation of the inter-
vention (allergic rhinitis-related contacts with health ser-
vices and quantities of allergic rhinitis medication used
over the six week period). Non-responders will receive
one telephone reminder and the opportunity to com-
plete the questionnaire by telephone if they prefer this
to returning the postal questionnaire.
As described above, semi-structured interviews will be
used to collect data about participants’ experiences of
the intervention. These will be conducted by telephone
for pharmacy customers and either by telephone or face-
to-face for pharmacy staff, as preferred by the inter-
viewee. Data will be recorded manually by the researcher
using written field notes, recorded on a data collection
form developed for this purpose.
Post-recruitment retention strategies
All participating community pharmacies will be contac-
ted by telephone within four weeks of commencing cus-
tomer recruitment to ensure that they are experiencing
no problems with the study procedures. Support from
the study researcher will be offered to pharmacy staff to
resolve any such problems. A newsletter will be sent to
all pharmacies during the intervention period reminding
staff of the study procedures, and giving feedback about
customer recruitment to date and tips on how to en-
hance recruitment. These tips will be a reminder of the
strategies suggested during training, but will also be in-
formed by feedback from the routine telephone contacts
made with pharmacy staff in the four weeks after cus-
tomer recruitment commences. Recruitment of cus-
tomers will be monitored for each community pharmacy
throughout the four-month recruitment period. Pharma-
cies that are not reaching target recruitment will be
offered one-to-one support by the study researcher. If
the problem continues into the second month of the
recruitment period, two solutions will be considered:
pharmacies that have successfully reached their recruit-
ment target will be asked to continue recruiting more
customers, and/or additional community pharmacies
will be recruited and trained from the list of those
expressing an interest to the original mailed invitation
to participate.
Recruited pharmacy customers whose completed
one-week questionnaire has not been received by the
research team three weeks post-recruitment, will receive
a reminder from the study researcher. Reminders will be
issued by telephone or email as indicated in the
customers’ contact details provided at recruitment.
Attempts to contact non-responders will continue until
contact is made or for a maximum of one week. A
similar process will be followed for the six-week
questionnaire.
Data management and analysis
Quantitative analysis
Data will be entered into Statistical Package for the
Social Sciences (Version 20.0, IBM, UK Head Office,
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IBM United Kingdom Limited, PO Box 41, North
Harbour, Portsmouth, Hampshire, PO6 3AU.) for ana-
lysis including: patient level descriptive statistics; inter-
group comparisons of intervention and usual care
groups (for example, cluster adjusted chi-squared test);
and intra-group comparisons (for example, cluster ad-
justed McNemars test) based on the generalized estimat-
ing equations (GEE) approach. Effect size estimates and
the intra-cluster correlation coefficient (ICC) will be
calculated to inform the sample size calculation for a
definitive RCT.
Economic analysis
Pharmacy staff ’s time inputs will be valued using standard
unit costs incorporating salaries, oncosts, capital and over-
heads. Out-of-pocket patient costs (for example, medica-
tions) and productivity will be estimated using questions
from the baseline and follow-up questionnaires; medica-
tions will be costed using market prices and productivity
will be valued using age/sex specific average gross wage
rates. The feasibility of using the EQ-5D to track changes
in health related QOL - to enable the estimation of quality
adjusted life years (QALYs) - will also be assessed using
data from this instrument in the patient questionnaires. A
cost-utility analysis will be undertaken, adopting both a
health service and societal perspective.
Qualitative analysis
Qualitative data will be stored and organized using
Microsoft Excel (Microsoft Limited, Microsoft Campus,
Thames Valley Park, Reading, Berkshire, RG6 1WG,
United Kingdom.), and analyzed using thematic descrip-
tive analysis based on the research questions (RQs
A1-A4), but alert to any unexpected experiences and
views. The field notes collected by the researcher during
post-intervention interviews will be transcribed into
Excel. These data will be grouped together by themes
emerging and reported descriptively.
Sample size considerations
Since this is a pilot RCT, no formal sample size calcula-
tion is necessary [36] although sufficient numbers are
required in each pharmacy to estimate effect sizes and
give a reliable ICC that will inform a future full evalu-
ation. Hence, we aim to retain at least 10 pharmacies
(five per arm) with 10 patients in each pharmacy. To
allow for attrition, we initially aim to recruit 12 pharma-
cies (six per arm) each of which will be asked to recruit
12 patients (that is, a total sample size of 144 patients).
In the event of insufficient recruitment of pharmacy cus-
tomers, or if any pharmacies drop out following recruit-
ment, additional pharmacies from the list of those
expressing an interest in participating will be selected to
boost recruitment numbers.
The sample sizes for the two qualitative components
(sub-sample of intervention customers (n = 18) and
intervention pharmacy staff (n = 6)) are pragmatic and
are considered sufficient to provide some feedback on
the delivery and acceptability of the intervention.
Trial status
The study began in April 2012. At the time of submission,
12 community pharmacies have been recruited. Pharmacy
staff from the six intervention pharmacies (three in each
of Grampian and Greater Glasgow & Clyde Health Board
areas) have been trained and recruitment of community
pharmacy customers commenced at the end of June 2012.
Pharmacy customer recruitment is ongoing and monthly
targets are being met.
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